Oncor's test predicts prostate cancer recurrence
This article was originally published in Clinica
Tests for HER-2/neu gene amplification may be useful in assessing patients with prostate cancer, say US researchers at Albany Medical College. In their preliminary study, HER-2/neu amplification correlated with tumour grade. It predicted disease recurrence, and could be useful for planning treatment, the researchers reported in Cancer (June 1).